Somatostatin Receptor-positive GEP-NET
1 clinical trials · Condition
◉ Watch Somatostatin Receptor-positive GEP-NET
| Record | Firm | Date |
|---|---|---|
| A Post Marketing Surveillance on Lutathera® in Patients With Somatostatin Receptor Positive Gastroenteropancreatic Neuroendocrine Tumor in Korea (NCT04946305) | Novartis Pharmaceuticals | 2022-05-10 |
Track Somatostatin Receptor-positive GEP-NET automatically
Every clearance here is in the API, with alerts when new ones post.